1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Opium (Opioid) Addiction-Pipeline Insights, 2014

SUMMARY
DelveInsight’s,“ Opium (Opioid) Addiction-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Opium (Opioid) Addiction. This report provides information on the therapeutic development based on the Opium (Opioid) Addiction dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Opium (Opioid) Addiction pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Opium (Opioid) Addiction and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Opium (Opioid) Addiction
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Opium (Opioid) Addiction-Pipeline Insights, 2014
Table of Contents
- Opium (Opioid) Addiction Overview
- Opium (Opioid) Addiction Pipeline Therapeutics
- Opium (Opioid) Addiction Therapeutics under Development by Companies
- Opium (Opioid) Addiction Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Opium (Opioid) Addiction Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Opium (Opioid) Addiction Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Opium (Opioid) Addiction Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Opium (Opioid) Addiction - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Opium (Opioid) Addiction - Discontinued Products
- Opium (Opioid) Addiction - Dormant Products
- Companies Involved in Therapeutics Development for Opium (Opioid) Addiction
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Opium (Opioid) Addiction, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Opium (Opioid) Addiction Assessment by Monotherapy Products
- Opium (Opioid) Addiction Assessment by Combination Products
- Opium (Opioid) Addiction Assessment by Route of Administration
- Opium (Opioid) Addiction Assessment by Stage and Route of Administration
- Opium (Opioid) Addiction Assessment by Molecule Type
- Opium (Opioid) Addiction Assessment by Stage and Molecule Type
- Opium (Opioid) Addiction Therapeutics - Discontinued Products
- Opium (Opioid) Addiction Therapeutics - Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Opium (Opioid) Addiction, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Opium (Opioid) Addiction Assessment by Monotherapy Products
- Opium (Opioid) Addiction Assessment by Combination Products
- Opium (Opioid) Addiction Assessment by Route of Administration
- Opium (Opioid) Addiction Assessment by Stage and Route of Administration
- Opium (Opioid) Addiction Assessment by Molecule Type
- Opium (Opioid) Addiction Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
North America Opioid Market Analysis By Product, By Application And Segment Forecasts To 2024

North America Opioid Market Analysis By Product, By Application And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • August 2016
  • by Grand View Research

The North America opioid market is expected to reach USD 18.5 billion by 2024, according to a new report by Grand View Research, Inc. Favorable regulations and healthcare reforms are providing an environment, ...

Global Market Study on Opioids: Widespread Usage in Treatment of Cancer to Drive the Growth of Opioids Market During the Forecast Period

Global Market Study on Opioids: Widespread Usage in Treatment of Cancer to Drive the Growth of Opioids Market During the Forecast Period

  • $ 4900
  • Industry report
  • August 2016
  • by Persistence Market Research

Opioids are naturally occurring opiates and synthetic and semi-synthetic drugs that act on opioid receptors in the brain and can cause dependence due to their euphoric effects. Opioids are majorly categorized ...

PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA

PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA

  • $ 3080
  • Industry report
  • September 2016
  • by MP Advisors

Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing ...


Download Unlimited Documents from Trusted Public Sources

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

Opioid and Anesthetics Market in Australia

  • December 2016
    5 pages
  • Opioid  

    Anesthetics  

    Analgesic  

  • Australia  

View report >

Related Market Segments :

Opioid

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.